Efficacy of rintatolimod in the treatment of chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME).
Mitchell, William M · Expert review of clinical pharmacology · 2016 · DOI
Quick Summary
This review examines rintatolimod, a potential ME/CFS treatment that works by activating the immune system's antiviral defenses. The drug has shown promising results in clinical trials, with patients experiencing meaningful improvements in their symptoms and few serious side effects. This is important because ME/CFS currently has no approved medications, and rintatolimod represents one of the most advanced treatment options in development.
Why It Matters
ME/CFS patients have no FDA-approved medications, making this review of rintatolimod's clinical development particularly significant. Understanding the current evidence for this most-advanced investigational treatment helps patients and clinicians make informed decisions about participation in future trials or regulatory approval pathways.
Observed Findings
Rintatolimod achieved statistically significant improvements in primary endpoints in Phase II and Phase III double-blind, randomized, placebo-controlled trials
The drug demonstrated a generally well-tolerated safety profile across clinical trials in the United States and Europe
Rintatolimod selectively activates TLR3 without triggering other major innate immunity pathways, potentially reducing side effects
The drug activates interferon-stimulated proteins (2'-5' adenylate synthetase, protein kinase R) that are induced by dsRNA
Open-label trial data supported the findings from blinded, placebo-controlled trials
Inferred Conclusions
Rintatolimod is the most advanced pharmaceutical in clinical development for CFS/ME, with evidence of efficacy and tolerability
The selective TLR3 agonist mechanism appears to activate relevant antiviral immune pathways without broad off-target activation
Immune dysregulation appears to play a significant role in CFS/ME pathophysiology, supporting rationale for immunomodulatory approaches
Remaining Questions
What are the long-term safety and sustained efficacy outcomes with rintatolimod treatment?
Which ME/CFS patient subgroups are most likely to benefit from rintatolimod therapy?
What This Study Does Not Prove
This review does not present new clinical trial data and cannot independently confirm rintatolimod's efficacy—it synthesizes existing published studies. The review also does not definitively establish that immune dysregulation is the primary cause of ME/CFS, though it presents evidence supporting this hypothesis. Long-term safety and durability of treatment benefits remain to be fully established.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Contribute
Private, reviewed by a human. Not a public comment thread.